Jewett-Cameron Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results

(NASDAQ:JCTC), Company to host webcast today, December 1, 2025, at 4:30 p.m. Eastern time NORTH PLAINS, Ore., Dec. 01, 2025 (GLOBE NEWSWIRE) — Jewett-Cameron Trading Company Ltd. (the “Company”; Nasdaq: JCTC), a company committed to innovative products that enrich outdoor spaces, today announced operational and financial results for the fiscal 2025 full year and fourth […]

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

(NASDAQ:CRBU), KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it

Superior Group of Companies to Participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference

(NasdaqGM:SGC), ST. PETERSBURG, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) today announced that Chairman and Chief Executive Officer, Michael Benstock, and President and Chief Financial Officer, Mike Koempel, will present at NobleCon21, Noble Capital Markets' 21st Annual Emerging Growth Equity Conference in Boca Raton, FL on Wednesday, December

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:SLDB), CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 23,284 restricted stock units (“RSUs”) to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:AKBA), CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics(R), Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 22,576 shares of Akebia's common stock on November 28, 2025. The options were granted as

XPO Provides North American LTL Operating Data for November 2025

(NYSE:XPO), GREENWICH, Conn., Dec. 01, 2025 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, today reported certain preliminary LTL segment operating metrics for November 2025. LTL tonnage per day decreased 5.4%, as compared with November 2024, attributable to a year-over-year decrease of 2.2% in shipments per day and

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:BMEA), SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase 7,500 shares of the Company's

Safe Bulkers, Inc. Announces a Ten Million Shares of Common Stock Repurchase Program

(NYSE:SB),(NYSE:SB-PC),(NYSE:SB-PD), MONACO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Safe Bulkers, Inc. (the Company) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that it has authorized a program under which it may from time to time in the future purchase up to 10,000,000 shares of the Company's common stock. If the maximum

Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting

(NasdaqGM:AVDL), NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 17(A) (AS AMENDED BY SECTION 3 OF APPENDIX 4) OF THE IRISH TAKEOVER

Alector to Participate in the Bank of America CNS Therapeutics Conference

(NASDAQ:ALEC), SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8,

Scroll to Top